Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says

Sensei Biotherapeutics (NASDAQ:SNSE) had its target price lifted by equities researchers at Oppenheimer from $3.50 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a research report on Friday.

Sensei Biotherapeutics Trading Up 17.2 %

Shares of NASDAQ SNSE opened at $0.51 on Friday. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The firm’s 50-day moving average price is $0.47 and its 200-day moving average price is $0.49. The stock has a market capitalization of $12.70 million, a price-to-earnings ratio of -0.42 and a beta of 0.16.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI grew its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,575 shares of the company’s stock after purchasing an additional 35,575 shares during the quarter. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent quarter. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.